NCT05314855Completed
Brain Clock and Insulin Resistance
Role of the Central Brain Clock in the Pathophysiology of Insulin Resistance
Source: ClinicalTrials.gov · Last updated 7 Jan 2026
Brief summary (registry, in English)
In this observational cohort study the investigators will determine the activity rhythm of the suprachiasmatic nucleus in humans with progressive stages of insulin resistance, using advanced functional brain imaging (7 Tesla functional MRI).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 28 (actual)
- First submitted
- 7 Mar 2022
- Start date
- 4 Jan 2023
- Primary completion date
- 18 Jan 2025
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Diseases
- Type 2 diabetes
- NCT number
- NCT05314855
What you commit to
- Study type: Observational
- Participants enrolled: 28
- From 4 Jan 2023 to the primary completion date, 18 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Crossing \> 2 time zones in the 3 months before the study
- Patients with type 2 DM receiving insulin treatment or glucagon-like peptide (GLP) 1 agonists
Other illness
- Active psychiatric disorder (including circadian rhythm sleep disorder) as defined in Diagnostic and Statistical Manual of Mental Disorders (DSM) 5
- Disorders of the central nervous system (Early-onset dementia, stroke, epilepsy, Parkinson's disease, brain tumor)
- Severe visual impairment (WHO classification)
Other
- An extreme chronotype (midpoint of sleep on free days (MSFsc) before 2:00 or after 6:00).
- Shift workers
- MRI contraindications
Who the study is looking for
- Group 1: obese people with normal insulin sensitivity
- age 25-65 years
- BMI\>30
- fasting plasma insulin ≤62 pmol/L
- fasting plasma glucose \<5.6 mmol/L
- Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) ≤ 4.5
- Group 2: obese people with insulin resistance
- age 25-65 years
- BMI\>30
- fasting plasma insulin \>62 pmol/L
- not fulfilling the American Diabetes Association (ADA) criteria for type 2 DM
- Group 3: obese subjects with overt type 2 DM
- age 25-65 years
- BMI\>30
- diagnosis type 2 DM according to ADA criteria
Age in the registry: 25 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam University Medical Centers, location AMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.